Literature DB >> 15655264

Pathological proteins in Parkinson's disease: focus on the proteasome.

Heather Snyder1, Benjamin Wolozin.   

Abstract

Parkinson's disease (PD) is a multifactorial disease that appears to arise from the effects of both genetic and environmental influences. Pesticides and heavy metals are the principle environmental factors that appear to impact on PD. The known genetic factors include multiple genes that have been identified in related parkinsonian syndromes, as well as alpha-synuclein. Genes associated with either PD or Parkinson-related disorders include parkin, DJ-1, ubiquitin C-terminal hydrolase isozyme L1 (UCH-L1), nuclear receptor-related factor 1, and alpha-synuclein. Alpha-synuclein is particularly notable because it aggregates readily and is the main component of Lewy bodies (LBs). Aggregated alpha-synuclein binds the proteasome and potently inhibits proteasomal activity. Because ubiquitin accumulates in LBs, and parkin and UCH-L1 also interact with the ubiquitin proteasomal system, proteasomal dysfunction is thought to contribute to the pathophysiology of PD. Increasing numbers of experiments suggest that neurotoxins might interact with alpha-synuclein or other Parkinson-related proteins to contribute to the pathophysiology of PD. Transgenic animal models overexpressing alpha-synuclein develop age-dependent motor dysfunction and inclusions in the brain stem that contain alpha-synuclein. These models are very helpful in elucidating the pathophysiology of PD but do not completely recapitulate the disease process. The relationship between these transgenic models and PD is a subject of intense investigation.

Entities:  

Mesh:

Substances:

Year:  2004        PMID: 15655264     DOI: 10.1385/JMN:24:3:425

Source DB:  PubMed          Journal:  J Mol Neurosci        ISSN: 0895-8696            Impact factor:   3.444


  97 in total

1.  Impact of ageing on proteasome structure and function in human lymphocytes.

Authors:  Géraldine Carrard; Marc Dieu; Martine Raes; Olivier Toussaint; Bertrand Friguet
Journal:  Int J Biochem Cell Biol       Date:  2003-05       Impact factor: 5.085

2.  Dying back type axonal degeneration of sensory nerve terminals in muscle spindles of the gracile axonal dystrophy (GAD) mutant mouse.

Authors:  K Oda; K Yamazaki; H Miura; H Shibasaki; T Kikuchi
Journal:  Neuropathol Appl Neurobiol       Date:  1992-06       Impact factor: 8.090

3.  Chaperone-like activity of synucleins.

Authors:  J M Souza; B I Giasson; V M Lee; H Ischiropoulos
Journal:  FEBS Lett       Date:  2000-05-26       Impact factor: 4.124

4.  Both familial Parkinson's disease mutations accelerate alpha-synuclein aggregation.

Authors:  L Narhi; S J Wood; S Steavenson; Y Jiang; G M Wu; D Anafi; S A Kaufman; F Martin; K Sitney; P Denis; J C Louis; J Wypych; A L Biere; M Citron
Journal:  J Biol Chem       Date:  1999-04-02       Impact factor: 5.157

5.  alpha-Synuclein shares physical and functional homology with 14-3-3 proteins.

Authors:  N Ostrerova; L Petrucelli; M Farrer; N Mehta; P Choi; J Hardy; B Wolozin
Journal:  J Neurosci       Date:  1999-07-15       Impact factor: 6.167

6.  Familial Parkinson disease gene product, parkin, is a ubiquitin-protein ligase.

Authors:  H Shimura; N Hattori; S i Kubo; Y Mizuno; S Asakawa; S Minoshima; N Shimizu; K Iwai; T Chiba; K Tanaka; T Suzuki
Journal:  Nat Genet       Date:  2000-07       Impact factor: 38.330

7.  DJ-1, a novel oncogene which transforms mouse NIH3T3 cells in cooperation with ras.

Authors:  D Nagakubo; T Taira; H Kitaura; M Ikeda; K Tamai; S M Iguchi-Ariga; H Ariga
Journal:  Biochem Biophys Res Commun       Date:  1997-02-13       Impact factor: 3.575

8.  An in vitro model of Parkinson's disease: linking mitochondrial impairment to altered alpha-synuclein metabolism and oxidative damage.

Authors:  Todd B Sherer; Ranjita Betarbet; Amy K Stout; Serena Lund; Melisa Baptista; Alexander V Panov; Mark R Cookson; J Timothy Greenamyre
Journal:  J Neurosci       Date:  2002-08-15       Impact factor: 6.167

9.  Genetic analysis of Nurr1 haplotypes in Parkinson's disease.

Authors:  Eng-King Tan; Henry Chung; Yi Zhao; Hui Shen; V R Chandran; Chris Tan; Mei-lin Teoh; Yuan Yih; Ratnagopal Pavanni; Meng-Cheong Wong
Journal:  Neurosci Lett       Date:  2003-08-28       Impact factor: 3.046

10.  Molecular cloning of cDNA encoding an unrecognized component of amyloid in Alzheimer disease.

Authors:  K Uéda; H Fukushima; E Masliah; Y Xia; A Iwai; M Yoshimoto; D A Otero; J Kondo; Y Ihara; T Saitoh
Journal:  Proc Natl Acad Sci U S A       Date:  1993-12-01       Impact factor: 11.205

View more
  14 in total

Review 1.  Location, location, location: altered transcription factor trafficking in neurodegeneration.

Authors:  Charleen T Chu; Edward D Plowey; Ying Wang; Vivek Patel; Kelly L Jordan-Sciutto
Journal:  J Neuropathol Exp Neurol       Date:  2007-10       Impact factor: 3.685

Review 2.  Agrochemicals, α-synuclein, and Parkinson's disease.

Authors:  Blanca A Silva; Leonid Breydo; Anthony L Fink; Vladimir N Uversky
Journal:  Mol Neurobiol       Date:  2012-08-30       Impact factor: 5.590

3.  6-OHDA generated ROS induces DNA damage and p53- and PUMA-dependent cell death.

Authors:  Alison I Bernstein; Sean P Garrison; Gerard P Zambetti; Karen L O'Malley
Journal:  Mol Neurodegener       Date:  2011-01-06       Impact factor: 14.195

4.  Lewy bodies.

Authors:  Clifford W Shults
Journal:  Proc Natl Acad Sci U S A       Date:  2006-01-31       Impact factor: 11.205

5.  Role of α-synuclein penetration into the membrane in the mechanisms of oligomer pore formation.

Authors:  Igor F Tsigelny; Yuriy Sharikov; Wolfgang Wrasidlo; Tania Gonzalez; Paula A Desplats; Leslie Crews; Brian Spencer; Eliezer Masliah
Journal:  FEBS J       Date:  2012-02-27       Impact factor: 5.542

6.  Parkin reverses intracellular beta-amyloid accumulation and its negative effects on proteasome function.

Authors:  Kenneth M Rosen; Charbel E-H Moussa; Han-Kyu Lee; Pravir Kumar; Tohru Kitada; Gangjian Qin; Qinghao Fu; Henry W Querfurth
Journal:  J Neurosci Res       Date:  2010-01       Impact factor: 4.164

7.  MPP+-induces PUMA- and p53-dependent, but ATF3-independent cell death.

Authors:  Alison I Bernstein; Karen L O'Malley
Journal:  Toxicol Lett       Date:  2013-03-14       Impact factor: 4.372

Review 8.  Catecholamine autotoxicity. Implications for pharmacology and therapeutics of Parkinson disease and related disorders.

Authors:  David S Goldstein; Irwin J Kopin; Yehonatan Sharabi
Journal:  Pharmacol Ther       Date:  2014-06-16       Impact factor: 12.310

Review 9.  A critical evaluation of the ubiquitin-proteasome system in Parkinson's disease.

Authors:  Casey Cook; Leonard Petrucelli
Journal:  Biochim Biophys Acta       Date:  2009-02-03

Review 10.  Trends in the molecular pathogenesis and clinical therapeutics of common neurodegenerative disorders.

Authors:  Yahya E Choonara; Viness Pillay; Lisa C Du Toit; Girish Modi; Dinesh Naidoo; Valence M K Ndesendo; Sibongile R Sibambo
Journal:  Int J Mol Sci       Date:  2009-06-03       Impact factor: 6.208

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.